Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, ReaMetrix to Develop Dx Panels Based on BeadXpress Platform

NEW YORK (GenomeWeb News) - Illumina and ReaMetrix plan to develop molecular diagnostic panels for several diseases, the companies said today.

 
The panels will "help predict the risk of disease, enable earlier intervention, and guide therapy," Jay Flatley, Illumina president and CEO, said in a statement.
 
Terms of the agreement call for Illumina to supply its VeraCode technology and other reagents while ReaMetrix will develop, validate, and market the panels.
 
The panels will be based on Illumina's yet-to-be-released BeadXpress platform, which the company plans to launch before the end of the year.
 
As part of the deal, ReaMetrix will gain non-exclusive rights to market the products in India while Illumina will be allowed to market the tests elsewhere in the world.
 
ReaMetrix will drive market development activities from its Bangalore, India, operation, the companies said.
 
Financial details were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.